There is no maximum time limit for taking Mounjaro. The FDA label sets no end date for treatment, and the longest clinical trial data now extends past three years with a consistent safety profile. For most people, Mounjaro is prescribed as an ongoing medication, much like a blood pressure drug or statin, because the conditions it treats (type 2 diabetes and obesity) are chronic.
That said, “you can stay on it indefinitely” raises practical questions about what happens to your body over years of use, what happens if you stop, and whether your insurance will keep covering it. Here’s what the evidence shows.
What Three Years of Data Tell Us
The longest study of tirzepatide (Mounjaro’s active ingredient) followed participants for 176 weeks, just under three and a half years. At that point, people on the highest dose maintained an average weight reduction of 22.9%, and the safety profile looked essentially the same as it did at the 72-week mark. The most common side effects remained gastrointestinal: nausea, diarrhea, constipation, and vomiting. These were generally mild to moderate and tend to ease over time, particularly after the dose-escalation phase.
One concern that comes up frequently is pancreatitis. A meta-analysis of 17 randomized trials found that while tirzepatide does raise levels of certain pancreatic enzymes (amylase and lipase), those elevations did not translate into a higher risk of pancreatitis compared to placebo. The risk ratio at the 15 mg dose was 1.26, which was not statistically significant. That said, the researchers noted that longer-term data would strengthen these conclusions.
What Happens if You Stop
This is the strongest argument for staying on Mounjaro long-term. The SURMOUNT-4 trial studied people who lost at least 10% of their body weight on tirzepatide over 36 weeks, then randomly assigned half of them to continue the medication and half to switch to a placebo. The results were striking: within one year of stopping, 82% of participants in the placebo group regained more than 25% of the weight they had lost. About a third regained 50% to 75% of it, and nearly a quarter gained back 75% or more.
Only 54 out of 308 people who stopped the medication kept most of their weight loss. This pattern is not unique to Mounjaro. It reflects the biology of obesity itself. Your body actively works to return to its previous weight through hormonal signals that increase hunger and reduce energy expenditure. Mounjaro counteracts those signals. Remove the medication, and the signals return.
How Mounjaro Affects Your Metabolism
One encouraging finding: tirzepatide does not appear to worsen the metabolic slowdown that typically accompanies weight loss. When you lose weight through calorie restriction alone, your body’s energy expenditure drops more than expected for your new size, a phenomenon called metabolic adaptation. A study published in Cell Metabolism found that tirzepatide had no negative impact on this process in humans and actually increased fat oxidation, meaning the body burned a higher proportion of fat for fuel. In animal studies, tirzepatide actively reduced the metabolic slowdown that occurred in calorie-restricted mice.
The medication also reduced appetite and calorie intake during meals, which helps explain why weight loss is maintained as long as someone continues treatment.
Muscle and Bone Loss Over Time
Any significant weight loss, whether from medication, diet, or surgery, comes with some loss of lean muscle mass. With tirzepatide, roughly 34% of total weight lost came from lean mass in the SURMOUNT-1 trial. That means about two-thirds of the weight lost was fat, which is a reasonable ratio, but the muscle loss is real and worth paying attention to over years of treatment.
MRI studies have added some nuance. While muscle volume decreased with tirzepatide use, the reductions were largely in line with what researchers would predict based on the amount of weight lost, a person’s age, and their health status. At the 5 mg and 10 mg doses, muscle volume loss was not significantly greater than expected. At 15 mg, it was slightly higher than predicted. Importantly, both muscle fat infiltration (fat stored within the muscle itself, which impairs muscle quality) decreased across all doses. So the remaining muscle was leaner and potentially healthier.
If you’re planning to stay on Mounjaro long-term, resistance training and adequate protein intake are the most effective ways to preserve muscle mass. There is currently no human data confirming direct beneficial effects of the medication on bone or muscle tissue.
Finding the Right Maintenance Dose
Long-term use doesn’t necessarily mean staying on the highest dose. The approved maintenance doses for weight management range from 5 mg to 15 mg per week, and prescribers are advised to choose based on both treatment response and tolerability. If you’re experiencing persistent side effects at a higher dose, stepping down to a lower maintenance dose is a standard option.
The 2.5 mg starting dose is specifically intended for the initial ramp-up period and is not considered a maintenance dose. From there, increases happen in 2.5 mg increments with at least four weeks between each step. Some people reach their goals at 5 mg or 10 mg and never need the maximum dose. Others need 15 mg. Your prescriber will typically look at your weight trajectory, blood sugar control, and side effect burden to find the dose that balances effectiveness with comfort.
Insurance Coverage for Ongoing Use
Even though the medication can be taken indefinitely from a medical standpoint, insurance coverage requires periodic reauthorization. The specifics vary by plan, but the general pattern is that your insurer will ask your prescriber to document a “positive clinical response.” For type 2 diabetes, that typically means improved blood sugar levels. For weight management (under the Zepbound brand), it usually means continued weight loss or maintenance of weight already lost.
Reauthorization cycles vary. Some plans review every 6 months, others annually. If your prescriber can document that you’re responding to the medication, coverage generally continues. The bigger challenge for many people is that some insurance plans don’t cover GLP-1 medications for weight management at all, or impose strict criteria around BMI thresholds and comorbidities. If you’re taking Mounjaro specifically for type 2 diabetes, coverage tends to be more straightforward since it’s the FDA-approved indication for that brand.